Four presentations highlight significant treatment gaps in isolated dystonia and new research providing mechanistic rationale for targeting muscarinic cholinergic receptors for treating movement disorders BOSTON, Mass., October 1, 2026 — Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 […] The post Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders appeared first on Vima Therapeutics .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules